ENDRA Life Sciences Inc. — Form 10-Q
Filed November 16, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Alexander Tokman (CEO/Chairman) and Richard Jacroux (CFO) signed standard Sarbanes-Oxley Section 302 and 906 certifications for the Q3 2026 10-Q (period ending September 30, 2026, filed November 16, 2026). Both officers certified the accuracy of financial statements and effectiveness of internal controls. No specific transactions, financial results, or operational changes are detailed in these certification exhibits.
Why this rating
Routine SOX compliance filing. No new business developments, transactions, or material changes disclosed. Boilerplate certification exhibits.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.